News

All news

2020-03-13

ACCORD HEALTHCARE LAUNCH AZACITIDINE 25 MG/ML

Accord Healthcare is delighted to announce the launch of Azacitidine 25 mg/mL Powder for Suspension for Injection.

This medicine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate-2 and high-risk myelodysplastic syndromes (MDS), certain types of chronic myelomonocytic leukaemia (CMML) and certain types of acute myeloid leukaemia (AML).

Please refer to the Summary of Product Characteristics (SPC) for further information. The SPC is available from www.hpra.ie and for Healthcare Professionals in the products section of this website. 

For further information please contact Accord in Cork on 021-461 9040 or visit www.accord-healthcare.ie

Date of Preparation: March 2020. IE-01484

All news